Drug Development Pipeline

Our drug development efforts target cancer, Alzheimer's disease, thrombosis, HIV/AIDS and other viral diseases. In addition, we have a number of other lead optimization programs within these disease areas.

Molecule	Therapeutic Area	Status
FLURIZAN™ (Global)	Alzheimer's Disease	Phase 3 (Global)
FLURIZAN™ (US)	Alzheimer's Disease	Phase 3 (US)
Azixa™ (MPC-6827)	Non-Small-Cell Lung Cancer	Phase 2
Azixa™ (MPC-6827)	Melanoma	Phase 2
Azixa™ (MPC-6827)	Glioblastoma	Phase 2
Vivecon™ (MPC-9055)	HIV (Maturation)	Phase 1
MPC-2130	Metastatic & Blood Cancers	Phase 1
MPC-0920	Thrombosis	Phase 1
MPC-3100	Cancer	Preclinical
MPI-451936	HIV (Fusion)	Preclinical
MPI-442690	Alzheimer's Disease	Preclinical
MPI-461359	HIV (Maturation)	Preclinical

The number of Americans with Alzheimer's disease will continue to grow - by 2050 the number of individuals with Alzheimer's could range from 11.3 million to 16 million.